Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, talks on the Phase III DESTINY-Breast04 trial (NCT03734029) which explored trastuzumab deruxtecan versus investigator's choice of chemotherapy for HER2-low metastatic breast cancer that has spread or cannot be surgically removed. Following the encouraging results of the DESTINY-Breast04, demonstrating impressive progression-free survival (PFS) and overall-survival (OS) with trastuzumab deruxtecan, the HER2-targeted antibody-drug conjugate (ADC) is set to become the new standard of care for patients with HER2-low breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
